TGF-β/Smad Signaling


The TGF-β family is generally classified into two sub-families, TGF-β ligands, and bone morphogenic protein (BMP) ligands. In canonical signaling, receptor activation lead to phosphorylation of a group of transcription factors called Smads. TGF-β ligands bind to type II receptors (TGF-β II) which recruit and phosphorylate type I receptor (TGF-β I) on serine/threonine residues. The TGF-β I then recruits and phosphorylates a receptor regulated Smad (R-Smad). The R-Smad binds to the common Smad (Co-Smad) and forms a heterodimeric complex. This complex then translocates into the cell nucleus where it binds with nuclear co-factors to regulate the transcription of various target genes. Dysregulation of TGF-β/Smad signaling pathway is associated with a number of pathological conditions including fibrosis, cancer, immunodeficiency, diabetes and cardiovascular diseases etc.
-
A8694 AI-10-49Summary: A selective leukemia oncoprotein CBFβ-SMHHC inhibitor -
B4942 Bryostatin 2Summary: Protein kinase C (PKC) activator -
B4943 Bryostatin 3Summary: protein kinase C activator -
B4964 (-)-epicatechinSummary: inducer of pancreatic β-cell regeneration -
B4965 (-)-epicatechin gallateSummary: major catechin in green tea -
B5858 ITD 1Summary: The first selective TGFβ inhibitor -
B5863 LX7101 HCLSummary: Dual LIM-kinase and ROCK inhibitor -
B5946 EW-71971 CitationTarget: BMP and Other Activin ReceptorsSummary: Selective inhibitor of TGF-β type I receptor kinase -
B5954 Dasatinib MonohydrateTarget: PDGFR|c-Kit|Bcr-Abl|SrcSummary: Inhibitor of ABL, SRC, KIT, PDGFR, and other tyrosine kinases. -
B6066 Bisindolylmaleimide VSummary: negative control for protein kinase C (PKC)-inhibitory activity

